Tags

Type your tag names separated by a space and hit enter

Statin use and risk of pancreatic cancer: a meta-analysis.
Cancer Causes Control. 2012 Jul; 23(7):1099-111.CC

Abstract

PURPOSE

Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer.

METHODS

We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran's Q test and the I(2) statistic.

RESULTS

We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74-1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81-1.08) and statin use (RR 0.97, 0.76-1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92-1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I(2) = 81 %).

CONCLUSIONS

In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention.

Authors+Show Affiliations

Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

22562222

Citation

Cui, Xiaobing, et al. "Statin Use and Risk of Pancreatic Cancer: a Meta-analysis." Cancer Causes & Control : CCC, vol. 23, no. 7, 2012, pp. 1099-111.
Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23(7):1099-111.
Cui, X., Xie, Y., Chen, M., Li, J., Liao, X., Shen, J., Shi, M., Li, W., Zheng, H., & Jiang, B. (2012). Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes & Control : CCC, 23(7), 1099-111. https://doi.org/10.1007/s10552-012-9979-9
Cui X, et al. Statin Use and Risk of Pancreatic Cancer: a Meta-analysis. Cancer Causes Control. 2012;23(7):1099-111. PubMed PMID: 22562222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin use and risk of pancreatic cancer: a meta-analysis. AU - Cui,Xiaobing, AU - Xie,Yue, AU - Chen,Min, AU - Li,Jun, AU - Liao,Xiaoming, AU - Shen,Jian, AU - Shi,Meng, AU - Li,Wenjing, AU - Zheng,Haoxuan, AU - Jiang,Bo, Y1 - 2012/05/05/ PY - 2011/12/09/received PY - 2012/04/21/accepted PY - 2012/5/8/entrez PY - 2012/5/9/pubmed PY - 2012/10/20/medline SP - 1099 EP - 111 JF - Cancer causes & control : CCC JO - Cancer Causes Control VL - 23 IS - 7 N2 - PURPOSE: Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer. METHODS: We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran's Q test and the I(2) statistic. RESULTS: We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74-1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81-1.08) and statin use (RR 0.97, 0.76-1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92-1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I(2) = 81 %). CONCLUSIONS: In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention. SN - 1573-7225 UR - https://www.unboundmedicine.com/medline/citation/22562222/Statin_use_and_risk_of_pancreatic_cancer:_a_meta_analysis_ L2 - https://doi.org/10.1007/s10552-012-9979-9 DB - PRIME DP - Unbound Medicine ER -